Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/GS-5885 fixed-dose combination ± ribavirin in treatment-naïve chronic genotype 1 HCV infection
2012-003387-43Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ledipasvir and sofosbuvir in hepatitis C virus infection (4 arms), sponsored by Gilead Sciences. Primary endpoint: SVR12 (sustained virologic response at 12 weeks post-treatment). Started Jan 2013; status: completed.
02
Drugs
ledipasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-003387-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003387-43.